✦ LIBER ✦

Cetuximab/folinic acid/fluorouracil/irinotecan

Book ID: 125388131
Publisher: Adis International Limited (now part of Wolters Kluwer Health)
Year: 2013
Weight: 128 KB
Volume: 1469
Category: Article
ISSN: 0114-9954
DOI: 10.1007/s40278-013-5790-y

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

664 PUBLICATION Cetuximab in combination

664 PUBLICATION Cetuximab in combination with irinotecan/5-fluorouracil (5-FU)/folinic acid (FA) (FOLFIRI) in the first-line treatment of metastatic colorectal cancer (mCRC)

📂 Article 📅 2005 🏛 Elsevier Science 🌐 English ⚖ 137 KB

Cetuximab in combination with irinotecan

Cetuximab in combination with irinotecan/5-fluorouracil/folinic acid (FOLFIRI) in the initial treatment of metastatic colorectal cancer: a multicentre two-part phase I/II study

✍ Jean-Luc Raoul; Jean-Luc Van Laethem; Marc Peeters; Catherine Brezault; Fares Hu 📂 Article 📅 2009 🏛 BioMed Central 🌐 English ⚖ 890 KB

Bevacizumab in association with de Gramo

Bevacizumab in association with de Gramont 5-fluorouracil/folinic acid in patients with oxaliplatin-, irinotecan-, and cetuximab-refractory colorectal cancer : A single-center phase 2 trial

✍ Bruno Vincenzi; Daniele Santini; Antonio Russo; Chiara Spoto; Olga Venditti; Sim 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 132 KB

## Abstract ## BACKGROUND: The aim of the current study was the investigation of the value of bevacizumab + 5‐fluorouracil(5–FU)/folinic acid in patients with advanced colorectal cancers who have exhausted standard chemotherapy options. ## METHODS: The authors included 48 heavily pretreated pati

702 PUBLICATION Cetuximab and irinotecan

702 PUBLICATION Cetuximab and irinotecan/5-fluorouracil (5-FU)/folinic acid (FA) (AIO) is active and safe in the first-line treatment of metastatic colorectal cancer (mCRC) expressing the epidermal growth factor receptor (EGFR)

📂 Article 📅 2005 🏛 Elsevier Science 🌐 English ⚖ 134 KB

Fluorouracil/folinic acid/irinotecan/oxa

Fluorouracil/folinic acid/irinotecan/oxaliplatin

✍ Gába, Aleš; Přidalová, Miroslava 📂 Article 📅 2013 🏛 Adis International Limited (now part of Wolters Kl ⚖ 129 KB

Cetuximab (C225, Erbitux) in combination

Cetuximab (C225, Erbitux) in combination with irinotecan, infusional 5-fluorouracil (5-FU) and folinic acid (FA) is safe and active in patients (pts) with metastatic colorectal cancer (CRC) expressing epidermal growth factor-receptor (EGFR). Results of a phase I study

📂 Article 📅 2002 🏛 Elsevier Science 🌐 English ⚖ 306 KB